Ombrabulin

Ombrabulin
IUPAC name (2S)-2-Amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide
Other names AVE-8062; AVE-8062A; AC7700; CS-39-L-Ser.HCl
Identifiers
CAS number	181816-48-8 Y, 253426-24-3 (HCl) Y
PubChem	6918405, 6918404 (HCl)
Jmol-3D images	Image 1
SMILES COC1=C(C=C(C=C1)/C=C\C2=CC(=C(C(=C2)OC)OC)OC)NC(=O)[C@H](CO)N
Properties
Molecular formula	C21H26N2O6
Molar mass	402.44 g mol−1
Y (verify) (what is: Y/N?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Ombrabulin is an experimental drug candidate discovered by Ajinomoto and under development by Sanofi-Aventis.^[1] It is currently in Phase III clinical trials for the treatment of advanced-stage soft-tissue sarcoma.^[1]

Ombrabulin was granted orphan drug status by the European Medicines Agency in April 2011.^[2]

Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.^[3][4]

References

1. ^ ^{a b} "Ombrabulin (AVE8062)". Sanofi-Aventis Oncology. http://www.sanofi-aventisoncology.com/wps/portal/oncology/pipeline/ombrabulin. 
2. ^ "Orphan Designation EU/3/11/853". European Medicines Agency. 15 April 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2011/04/human_orphan_000912.jsp&mid=WC0b01ac058001d12b&murl=menus/medicines/medicines.jsp&jsenabled=true. 
3. ^ Hori, K; Saito, S; Nihei, Y; Suzuki, M; Sato, Y (1999). "Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700". Japanese journal of cancer research : Gann 90 (9): 1026–38. PMID 10551334. 
4. ^ Hori, K; Saito, S; Kubota, K (2002). "A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs". British journal of cancer 86 (10): 1604–14. doi:10.1038/sj.bjc.6600296. PMC 2746587. PMID 12085211. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2746587.